Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation.

AIMS To gain insight in the prognosis and treatment of atrial fibrillation (AF) patients during 1-year follow-up in the Euro Heart Survey (EHS) on AF. METHODS AND RESULTS The EHS enrolled 5333 AF patients in 2003--2004. One-year follow-up data were available for 80%. Of first detected AF patients, 46% did not have a recurrence during 1 year, paroxysmal AF largely remained paroxysmal AF (80%), and 30% of persistent AF progressed to permanent AF. Many treatment changes occurred since baseline. Oral anticoagulation was started in 19% and discontinued in 16% of all patients. Of patients initially on rhythm control 27% did not receive rhythm control during follow-up, whereas 15% of patients initially on rate control received rhythm control. Mortality was highest in permanent AF (8.2%), but also substantial in first detected AF (5.7%). In multivariable analysis, sinus rhythm at baseline was associated with lower mortality, but no significant effect was observed regarding the application of either rhythm or rate control. CONCLUSION The EHS on AF provides unique prospective observational data on AF progression, long-term treatment, prognosis, and determinants of adverse outcome of the total clinical spectrum of AF in a European cardiology-based patient cohort.

[1]  E. Aliot,et al.  Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. , 2006, European heart journal.

[2]  Samuel Wann,et al.  [Guidelines for the management of patients with atrial fibrillation. Executive summary]. , 2006, Revista espanola de cardiologia.

[3]  Silvia G Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit , 2006, Journal of the American College of Cardiology.

[4]  Samuel Wann,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.

[5]  J. Seward,et al.  Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. , 2006, European heart journal.

[6]  M. Josephson,et al.  Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. , 2006, The American journal of cardiology.

[7]  B. Gersh,et al.  Effect of atrial fibrillation pattern on survival in a community-based cohort. , 2005, The American journal of cardiology.

[8]  Dietrich Andresen,et al.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. , 2005, European heart journal.

[9]  J. Finsterer,et al.  Factors influencing mortality in atrial fibrillation. Post hoc analysis of an observational study in outpatients. , 2005, International journal of cardiology.

[10]  S. Connolly,et al.  Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. , 2005, American heart journal.

[11]  B. Gersh,et al.  Outcome of patients with newly diagnosed atrial fibrillation at the Mayo Clinic and residing in that area. , 2004, The American journal of cardiology.

[12]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[13]  S. Saba,et al.  Epidemiology and determinants of outcome of admissions for atrial fibrillation in the United States from 1996 to 2001. , 2004, The American journal of cardiology.

[14]  A. Ducharme,et al.  Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Trials , 2003, Circulation.

[15]  Juan F Granada,et al.  A population-based study of mortality among patients with atrial fibrillation or flutter. , 2002, The American journal of medicine.

[16]  J. McMurray,et al.  Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study , 2001, Heart.

[17]  L. Køber,et al.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. , 1999, Circulation.

[18]  S. Lévy,et al.  Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. , 1999, Circulation.

[19]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[20]  R B D'Agostino,et al.  Impact of atrial fibrillation on mortality, stroke, and medical costs. , 1998, Archives of internal medicine.

[21]  F A Mathewson,et al.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.

[22]  E. Williams.  A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs , 1984 .

[23]  E. V. Vaughan Williams.  A classification of antiarrhythmic actions reassessed after a decade of new drugs. , 1984, Journal of clinical pharmacology.